Literature DB >> 9038345

Revertant mosaicism in epidermolysis bullosa caused by mitotic gene conversion.

M F Jonkman1, H Scheffer, R Stulp, H H Pas, M Nijenhuis, K Heeres, K Owaribe, L Pulkkinen, J Uitto.   

Abstract

Mitotic gene conversion acting as reverse mutation has not been previously demonstrated in human. We report here that the revertant mosaicism of a compound heterozygous proband with an autosomal recessive genodermatosis, generalized atrophic benign epidermolysis bullosa, is caused by mitotic gene conversion of one of the two mutated COL17A1 alleles. Specifically, the maternal allele surrounding the mutation site on COL17A1 (1706delA) showed reversion of the mutation and loss of heterozygosity along a tract of at least 381 bp in revertant keratinocytes derived from clinically unaffected skin patches; the paternal mutation (R1226X) remained present in all cell samples. Revertant mosaicism represents a way of natural gene therapy.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9038345     DOI: 10.1016/s0092-8674(00)81894-2

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   41.582


  56 in total

1.  Digenic junctional epidermolysis bullosa: mutations in COL17A1 and LAMB3 genes.

Authors:  M Floeth; L Bruckner-Tuderman
Journal:  Am J Hum Genet       Date:  1999-12       Impact factor: 11.025

Review 2.  Induced pluripotent stem cells in dermatology: potentials, advances, and limitations.

Authors:  Ganna Bilousova; Dennis R Roop
Journal:  Cold Spring Harb Perspect Med       Date:  2014-11-03       Impact factor: 6.915

3.  Piecing together the puzzle of cutaneous mosaicism.

Authors:  Amy S Paller
Journal:  J Clin Invest       Date:  2004-11       Impact factor: 14.808

Review 4.  Revertant mosaicism in skin: natural gene therapy.

Authors:  Joey E Lai-Cheong; John A McGrath; Jouni Uitto
Journal:  Trends Mol Med       Date:  2010-12-29       Impact factor: 11.951

5.  Somatic mosaicism in Wiskott--Aldrich syndrome suggests in vivo reversion by a DNA slippage mechanism.

Authors:  T Wada; S H Schurman; M Otsu; E K Garabedian; H D Ochs; D L Nelson; F Candotti
Journal:  Proc Natl Acad Sci U S A       Date:  2001-07-10       Impact factor: 11.205

6.  Epidermolysis bullosa. I. Molecular genetics of the junctional and hemidesmosomal variants.

Authors:  R Varki; S Sadowski; E Pfendner; J Uitto
Journal:  J Med Genet       Date:  2006-02-10       Impact factor: 6.318

Review 7.  Cutaneous mosaicism: right before our eyes.

Authors:  Jorge Frank; Rudolf Happle
Journal:  J Clin Invest       Date:  2007-05       Impact factor: 14.808

8.  Long-term survival of type XVII collagen revertant cells in an animal model of revertant cell therapy.

Authors:  Antoni Gostyński; Sara Llames; Marta García; María J Escamez; Lucía Martinez-Santamaria; Miranda Nijenhuis; Alvaro Meana; Hendri H Pas; Fernando Larcher; Anna M G Pasmooij; Marcel F Jonkman; Marcela Del Rio
Journal:  J Invest Dermatol       Date:  2013-07-24       Impact factor: 8.551

9.  Loss of heterozygosity or: how I learned to stop worrying and love mitotic recombination.

Authors:  J A Tischfield
Journal:  Am J Hum Genet       Date:  1997-11       Impact factor: 11.025

10.  Revertant mosaicism in junctional epidermolysis bullosa due to multiple correcting second-site mutations in LAMB3.

Authors:  Anna M G Pasmooij; Hendri H Pas; Maria C Bolling; Marcel F Jonkman
Journal:  J Clin Invest       Date:  2007-05       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.